title: [Microbiocenosis of the mucous membranes of the upper respiratory tract and its correction with acipol in the treatment of patients with acute respiratory virus infections].
abstract: Clinical and laboratory evaluation of the preparation Acipol in 45 children greatly susceptible to acute respiratory virus infections (ARVI) was carried out. Simultaneously with the clinical analysis, the study of the microflora of the mucous membranes of the upper respiratory tracts and intestine, as well as the levels of secretory IgA in saliva and coprofiltrates before and after treatment, was made. The inclusion of Acipol into the therapy of ARVI patients facilitated their clinical convalescence, uncomplicated course of the disease, correction of disturbances in the biocenosis of the upper respiratory tracts and increased infectious resistance.
authors.affiliation: Vladimirsky Regional Research Clinical Institute, Moscow, Russia.
authors.forename: E E
authors.initials: EE
authors.lastname: Tselipanova
authors.forename: V M
authors.initials: VM
authors.lastname: Shebekova
authors.forename: L V
authors.initials: LV
authors.lastname: Feklisova
authors.forename: K I
authors.initials: KI
authors.lastname: Savitskaia
authors.forename: N F
authors.initials: NF
authors.lastname: Danina
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000998:Antiviral Agents / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003289:Convalescence; D004064:Digestive System / Q000821:virology; D004341:Drug Evaluation; D006801:Humans; D007070:Immunoglobulin A / Q000276:immunology; D007223:Infant; D009092:Mucous Membrane / Q000821:virology*; D009297:Nasal Mucosa / Q000821:virology; D012141:Respiratory Tract Infections / Q000188:drug therapy / Q000821:virology*; D012463:Saliva / Q000276:immunology; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D007070:Immunoglobulin A